CD47 and non-Hodgkin lymphoma: Other additional anti-CD47 antibodies include IBI-88 (Letaplimab), AK117 (Ligufalimab), and TJ011133 (Lemzoparlimab) which are currently being investigated in combination therapies for the treatment of NHL, MDS, and AML.